FLIPL Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin is a natural compound that indirectly inhibits FLIPL by influencing the NF-κB signaling pathway. Its suppression of NF-κB activation leads to decreased FLIPL expression, altering its interaction with other components in apoptotic pathways. This indirect inhibition impacts cellular processes governed by FLIPL, contributing to the pharmacological effects of Curcumin. | ||||||
Embelin | 550-24-3 | sc-201555 sc-201555A | 10 mg 50 mg | $87.00 $332.00 | 5 | |
Embelin is a natural product that indirectly inhibits FLIPL by modulating the NF-κB signaling pathway. Its interference with NF-κB activation results in decreased FLIPL expression, influencing its role in apoptotic pathways. This indirect inhibition impacts cellular processes governed by FLIPL, contributing to the pharmacological effects of Embelin. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that indirectly affects FLIPL by modulating the NF-κB signaling pathway. Its inhibition of the proteasome prevents the degradation of IκBα, leading to decreased FLIPL expression. This indirect inhibition impacts cellular processes governed by FLIPL, contributing to the pharmacological effects of Bortezomib. | ||||||
Betulinic Acid | 472-15-1 | sc-200132 sc-200132A | 25 mg 100 mg | $115.00 $337.00 | 3 | |
Betulinic Acid is a natural product that indirectly inhibits FLIPL by modulating the NF-κB signaling pathway. Its interference with NF-κB activation results in decreased FLIPL expression, influencing its role in apoptotic pathways. This indirect inhibition impacts cellular processes governed by FLIPL, contributing to the pharmacological effects of Betulinic Acid. | ||||||
Birinapant | 1260251-31-7 | sc-503590 sc-503590A | 1 mg 5 mg | $160.00 $360.00 | ||
Birinapant is a SMAC mimetic that directly inhibits FLIPL by promoting caspase activation. Its interaction with FLIPL prevents its anti-apoptotic function, leading to the initiation of apoptotic cascades. This direct inhibition impacts cellular processes governed by FLIPL, contributing to the pharmacological effects of Birinapant. | ||||||
Obatoclax Mesylate | 803712-79-0 | sc-364221 sc-364221A | 5 mg 10 mg | $94.00 $138.00 | ||
Obatoclax is a BH3 mimetic that indirectly inhibits FLIPL by modulating the Bcl-2 family proteins. Its interaction with Bcl-2 proteins influences the mitochondrial apoptotic pathway, leading to decreased FLIPL expression. This indirect inhibition impacts cellular processes governed by FLIPL, contributing to the pharmacological effects of Obatoclax. | ||||||
Gossypol | 303-45-7 | sc-200501 sc-200501A | 25 mg 100 mg | $114.00 $225.00 | 12 | |
Gossypol is a natural product that indirectly inhibits FLIPL by modulating the NF-κB signaling pathway. Its interference with NF-κB activation results in decreased FLIPL expression, influencing its role in apoptotic pathways. This indirect inhibition impacts cellular processes governed by FLIPL, contributing to the pharmacological effects of Gossypol. | ||||||
YM 155 | 781661-94-7 | sc-364661 sc-364661A | 5 mg 25 mg | $129.00 $497.00 | 3 | |
YM155 is a survivin suppressant that indirectly inhibits FLIPL by modulating survivin levels. Its interference with survivin expression influences the apoptotic pathways associated with FLIPL, leading to decreased FLIPL activity. This indirect inhibition impacts cellular processes governed by FLIPL, contributing to the pharmacological effects of YM155. | ||||||
Q-VD-OPH | 1135695-98-5 | sc-222230 | 5 mg | $782.00 | 5 | |
Q-VD-OPh is a broad-spectrum caspase inhibitor that directly inhibits FLIPL by preventing caspase activation. Its interaction with caspases prevents their activation, disrupting the apoptotic cascades governed by FLIPL. This direct inhibition impacts cellular processes governed by FLIPL, contributing to the pharmacological effects of Q-VD-OPh. | ||||||